Lavelle Erin 4

What Happened
Erin Lavelle, a director of Avalyn Pharma (AVLN), received a derivative equity award for 26,978 shares on 2026-04-30. The award was reported at a $0.00 per-share acquisition price (no cash payment). This is a compensation/award transaction (not a purchase or sale).

Key Details

• Transaction date: 2026-04-30; Form 4 filed: 2026-05-01 (timely filing).
• Transaction type/code: Award/Grant (A); amount: 26,978 shares; reported price: $0.00.
• Vesting: 25% of the shares underlying the award became exercisable on Sept 12, 2025; the remaining 75% vest in 36 equal monthly installments thereafter, subject to continued service.
• Shares owned after transaction: Not disclosed in the information provided.
• This is a derivative award (compensation), not an immediate sale or market purchase.

Context
Awards like this are typically part of director compensation and reflect future potential ownership as vesting conditions are met; they do not, by themselves, indicate an immediate market purchase or sale. The filing was made within the standard SEC Form 4 timing window.